Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline

Ceftolozane/tazobactam

Gram-negative CXA-201

for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)

The EMA and FDA have respectively accepted for review Cubist’s Marketing Authorization Application and New Drug Application for its investigational antibiotic ceftolozane/tazobactam, for which the Company is seeking approval for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections…

Dificid

News & Press

26 Aug

Cubist to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Cubist Pharmaceuticals, Inc. today announced that it will present new data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9 in Washington, D.C.

Careers at Cubist

Alice

Meet Alice

Vice President of Medical Affairs, International

Alice was hired in the fall of 2013 as Vice President of Medical Affairs, International, charged with building Cubist’s Medical…

Investor Center

Cubist Pharmaceuticals Loading…
CBST (NASDAQ)